Henan Lingrui Pharmaceutical (600285.SH) announced on November 29 that on November 29, 2024, the company held the twelfth meeting of the ninth board of directors and the tenth meeting of the ninth board of supervisors, and approved the "Proposal on Authorizing the Use of Idle Own Funds for Money Management", agreeing to use idle own funds not exceeding RMB 2.2 billion for cash management, with funds within the quota available for rolling use.
羚锐制药(600285.SH)：拟使用不超过22亿元的闲置自有资金进行现金管理
Henan Lingrui Pharmaceutical (600285.SH): plans to use no more than 2.2 billion yuan of idle self-owned funds for cash management.
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Hot News
Updated